Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast

On Friday, Sanofi SA SNY reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency.The company reported third-quarter sales of 13.44 billion euros or $14.79 billion, beating the consensus of $13.97 billion.Sales increased 12.3% year over year and 15.7% on constant currency, led by solid growth from Dupixent, Pharma launches, vaccines, and Opella.The French drugmaker reported adjusted EPS of 2.86 euros or $1.57, up 12.2% ( ...